BioSpace News Archive

7 Hills Pharma, a clinical stage immunotherapy company focused on the development of drugs for treatment and prevention of cancer and infectious diseases, announced the appointment of Michael S. Perry, DVM, Ph.D., as its first Chairman of the Board of Managers.

Renalytix plc today announced the company will be presenting at the upcoming 41 st Annual Canaccord Genuity Virtual Global Growth Conference.

Athenex, Inc., a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced that the Company has entered into licensing agreements and strategic partnerships with Seqirus Pty Ltd, a subsidiary of CSL Limited, and AVIR Pharma Inc. for tirbanibulin.

MediWound Ltd., a fully-integrated biopharmaceutical company focused on next-generation bio-therapeutics solutions for tissue repair and regeneration, announced initiation of its phase I/II study of MW005 for the treatment of low-risk Basal Cell Carcinoma.

Iterum Therapeutics plc, a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, announced that it received a Complete Response Letter from the U.S. Food and Drug Administration for its New Drug Application for sulopenem etzadroxil/probenecid on July 23, 2021.

Castle Biosciences, Inc., a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions, announced that it will release its financial results for the second quarter and six months ended June 30, 2021, after the close of market on Monday, Aug. 9, 2021.

NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company, announced that the U.S. Food and Drug Administration has cleared an investigational new drug application for a Phase 1 study evaluating the company’s lead asset, NT-I7, a novel long-acting human interleukin-7, for the treatment of Kaposi Sarcoma in patients with or without infection with HIV.

Virios Therapeutics, Inc., a clinical-stage biotechnology company focused on advancing novel antiviral therapies to treat chronic pain and fatigue related diseases, announced that all 41 sites involved in its ongoing 460 patient Phase 2b fibromyalgia trial are now fully activated and enrolling patients.

Xenetic Biosciences, Inc., a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase of 4,629,630 shares of its common stock at a purchase price per share of $2.70, in a private placement priced at-the-market under Nasdaq rules.

MorphoSys AG announces an update of its financial guidance for 2021 after preliminary completion of the latest evaluation of MorphoSys’ half year 2021 financial performance.